Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy.

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-08-15 DOI:10.1158/1078-0432.CCR-24-0938

Ana Martínez-Riaño, Laura Mosteo, Paula Molero-Glez, Iván Márquez-Rodas, Ignacio Melero

引用次数: 0

Abstract

The presence of moieties denoting viral infection is crucial to mount powerful cytotoxic T-cell immune responses acting through innate receptors such as Toll-like receptor 3. For cancer immunotherapy, several safe analogues of viral double-stranded RNA are under clinical development following compelling evidence for efficacy in mouse models. See related article by van Eijck et al., p. 3447.

查看原文本刊更多论文

模拟病毒感染的双链 RNA，用于癌症免疫疗法。

病毒感染分子的存在对于通过 Toll 样受体 3 (TLR3) 等先天受体产生强大的细胞毒性 T 细胞免疫反应至关重要。在癌症免疫疗法方面，有几种安全的病毒双链 RNA（dsRNA）类似物在小鼠模型中的疗效令人信服，目前正在进行临床开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.

文献相关原料

公司名称	产品信息	采购帮参考价格